Literature DB >> 23271029

5-hydroxytryptamine actions in adipocytes: involvement of monoamine oxidase-dependent oxidation and subsequent PPARγ activation.

Sandra Grès1, Saioa Gomez-Zorita, Ana Gomez-Ruiz, Christian Carpéné.   

Abstract

Serotonin (5-HT) is a brain neurotransmitter instrumental for the antidepressant action of selective inhibitors of serotonin reuptake (SSRIs) while it also plays important roles in peripheral organs. Recently, the 5-HT oxidation products, 5-hydroxyindoleacetate and 5-methoxy-indoleacetate, have been shown to bind to peroxisome proliferator-activated receptor γ (PPARγ) and to enhance lipid accumulation in preadipocytes. Since we already reported that adipocytes exhibit elevated monoamine oxidase (MAO) and primary amine oxidase activities, we verified how adipocytes readily oxidize 5-HT, with the objective to determine whether such oxidation promotes PPARγ activation and lipid storage. To this aim, serotonin was tested on cultured 3T3 F442A preadipocytes and on human adipocytes. Results showed that 5-HT was oxidized by MAO in both models. Daily treatment of 3T3 F442A preadipocytes for 8 days with 100-500 μM 5-HT promoted triglyceride accumulation and emergence of adipogenesis markers. At 250 μM, 5-HT alone reproduced half of 50 nM insulin-induced adipogenesis, and exhibited an additive differentiating effect when combined with insulin. Moreover, the 5-HT-induced expression of PPARγ-responsive genes (PEPCK, aP2/FABP4) was blocked by GW 9662, a PPARγ-inhibitor, or by pargyline, a MAO-inhibitor. In human fat cells, 6-h exposure to 100 μM 5-HT increased PEPCK expression as did the PPARγ-agonist rosiglitazone. Since hydrogen peroxide, another amine oxidation product, did not reproduce such enhancement, we propose that serotonin can promote PPARγ activation in fat cells, via the indoleacetate produced during MAO-dependent oxidation. Such pathway could be involved in the adverse effects of several antidepressant SSRIs on body weight gain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271029     DOI: 10.1007/s00702-012-0959-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  26 in total

1.  Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.

Authors:  Claudia Binda; Milagros Aldeco; Werner J Geldenhuys; Marcello Tortorici; Andrea Mattevi; Dale E Edmondson
Journal:  ACS Med Chem Lett       Date:  2011-10-15       Impact factor: 4.345

2.  Short- and long-term insulin-like effects of monoamine oxidases and semicarbazide-sensitive amine oxidase substrates in cultured adipocytes.

Authors:  Christian Carpéné; Danièle Daviaud; Jeremie Boucher; Sandy Bour; Virgile Visentin; Sandra Grès; Carine Duffaut; Emi Fontana; Xavier Testar; Jean-Sébastien Saulnier-Blache; Philippe Valet
Journal:  Metabolism       Date:  2006-10       Impact factor: 8.694

3.  High expression of monoamine oxidases in human white adipose tissue: evidence for their involvement in noradrenaline clearance.

Authors:  N Pizzinat; L Marti; A Remaury; F Leger; D Langin; M Lafontan; C Carpéné; A Parini
Journal:  Biochem Pharmacol       Date:  1999-12-01       Impact factor: 5.858

4.  Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes.

Authors:  T Cadoudal; J M Blouin; M Collinet; F Fouque; G D Tan; E Loizon; E G Beale; K N Frayn; F Karpe; H Vidal; C Benelli; C Forest
Journal:  Diabetologia       Date:  2007-01-23       Impact factor: 10.122

Review 5.  Dietary inhibitors of monoamine oxidase A.

Authors:  Sarah E Dixon Clarke; Rona R Ramsay
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

6.  Increased primary amine oxidase expression and activity in white adipose tissue of obese and diabetic db-/- mice.

Authors:  Zsuzsa Iffiú-Soltész; Josep Mercader; Danielle Daviaud; Jérémie Boucher; Christian Carpéné
Journal:  J Neural Transm (Vienna)       Date:  2011-02-05       Impact factor: 3.575

7.  Adipose overexpression of phosphoenolpyruvate carboxykinase leads to high susceptibility to diet-induced insulin resistance and obesity.

Authors:  Sylvie Franckhauser; Sergio Muñoz; Ivet Elias; Tura Ferre; Fatima Bosch
Journal:  Diabetes       Date:  2006-02       Impact factor: 9.461

8.  Increased fatty acid re-esterification by PEPCK overexpression in adipose tissue leads to obesity without insulin resistance.

Authors:  Sylvie Franckhauser; Sergio Muñoz; Anna Pujol; Alba Casellas; Efren Riu; Pedro Otaegui; Benli Su; Fatima Bosch
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

9.  The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites.

Authors:  Tsuyoshi Waku; Takuma Shiraki; Takuji Oyama; Kanako Maebara; Rinna Nakamori; Kosuke Morikawa
Journal:  EMBO J       Date:  2010-08-17       Impact factor: 11.598

10.  Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.

Authors:  Min Lu; David A Sarruf; Saswata Talukdar; Shweta Sharma; Pingping Li; Gautam Bandyopadhyay; Sarah Nalbandian; WuQiang Fan; Jiaur R Gayen; Sushil K Mahata; Nicholas J Webster; Michael W Schwartz; Jerrold M Olefsky
Journal:  Nat Med       Date:  2011-05-01       Impact factor: 53.440

View more
  2 in total

1.  PPARγ upregulation induced by vagus nerve stimulation exerts anti-inflammatory effect in cerebral ischemia/reperfusion rats.

Authors:  Ying Jiang; Longling Li; Bin Liu; Yanhong Zhang; Qian Chen; Changqing Li
Journal:  Med Sci Monit       Date:  2015-01-21

2.  Pioglitazone could induce remission in major depression: a meta-analysis.

Authors:  Romain Colle; Delphine de Larminat; Samuel Rotenberg; Franz Hozer; Patrick Hardy; Céline Verstuyft; Bruno Fève; Emmanuelle Corruble
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-19       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.